← Back to headlines
Cue Biopharma Stock Drops 25% Despite Reverse Split Plan
Cue Biopharma's stock experienced a 25% decline, even after the company announced a 1-for-30 reverse split plan.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
